Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre–XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are freque...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2022-09-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/28/9/22-0458_article |
| _version_ | 1817982942848221184 |
|---|---|
| author | Yousra Kherabi Mathilde Fréchet-Jachym Christophe Rioux Yazdan Yazdanpanah Frédéric Méchaï Valérie Pourcher Jérôme Robert Lorenzo Guglielmetti |
| author_facet | Yousra Kherabi Mathilde Fréchet-Jachym Christophe Rioux Yazdan Yazdanpanah Frédéric Méchaï Valérie Pourcher Jérôme Robert Lorenzo Guglielmetti |
| author_sort | Yousra Kherabi |
| collection | DOAJ |
| description |
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre–XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006–2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
|
| first_indexed | 2024-04-13T23:26:40Z |
| format | Article |
| id | doaj.art-02df8e4ba8de4246b2e8b009dfa1db02 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-04-13T23:26:40Z |
| publishDate | 2022-09-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-02df8e4ba8de4246b2e8b009dfa1db022022-12-22T02:25:01ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592022-09-012891796180410.3201/eid2809.220458Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019Yousra KherabiMathilde Fréchet-JachymChristophe RiouxYazdan YazdanpanahFrédéric MéchaïValérie PourcherJérôme RobertLorenzo Guglielmetti Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre–XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006–2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events. https://wwwnc.cdc.gov/eid/article/28/9/22-0458_articletuberculosisMDR TBXDR TBbedaquilinelinezolidtuberculosis and other mycobacteria |
| spellingShingle | Yousra Kherabi Mathilde Fréchet-Jachym Christophe Rioux Yazdan Yazdanpanah Frédéric Méchaï Valérie Pourcher Jérôme Robert Lorenzo Guglielmetti Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 Emerging Infectious Diseases tuberculosis MDR TB XDR TB bedaquiline linezolid tuberculosis and other mycobacteria |
| title | Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 |
| title_full | Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 |
| title_fullStr | Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 |
| title_full_unstemmed | Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 |
| title_short | Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 |
| title_sort | revised definitions of tuberculosis resistance and treatment outcomes france 2006 2019 |
| topic | tuberculosis MDR TB XDR TB bedaquiline linezolid tuberculosis and other mycobacteria |
| url | https://wwwnc.cdc.gov/eid/article/28/9/22-0458_article |
| work_keys_str_mv | AT yousrakherabi reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT mathildefrechetjachym reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT christopherioux reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT yazdanyazdanpanah reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT fredericmechai reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT valeriepourcher reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT jeromerobert reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 AT lorenzoguglielmetti reviseddefinitionsoftuberculosisresistanceandtreatmentoutcomesfrance20062019 |